Nature Reviews Bioengineering, Journal Year: 2024, Volume and Issue: 2(11), P. 944 - 959
Published: July 15, 2024
Language: Английский
Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)
Published: Jan. 30, 2023
In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach to fight cancers. This consists of genetically engineered immune cells expressing surface receptor, called CAR, that specifically targets antigens expressed on tumor cells. hematological malignancies like leukemias, myeloma, and non-Hodgkin B-cell lymphomas, adoptive CAR-T shown efficacy in treating chemotherapy refractory patients. However, value this remains inconclusive context solid tumors is restrained by several obstacles including limited trafficking infiltration, presence an immunosuppressive microenvironment, well adverse events associated with such therapy. Recently, CAR-Natural Killer (CAR-NK) CAR-macrophages (CAR-M) were introduced complement/alternative for tumors. CAR-NK could be favorable substitute since they do not require HLA compatibility have toxicity. Additionally, might generated large scale from sources which would suggest them off-the-shelf product. CAR-M immunotherapy its capabilities phagocytosis, tumor-antigen presentation, broad currently being investigated. Here, we discuss emerging role CAR-T, CAR-NK, We also highlight advantages drawbacks compared Finally, prospective solutions potential combination therapies enhance CAR-cells immunotherapy.
Language: Английский
Citations
301
Cell, Journal Year: 2023, Volume and Issue: 186(19), P. 4235 - 4251.e20
Published: Aug. 21, 2023
Natural killer (NK) cells play indispensable roles in innate immune responses against tumor progression. To depict their phenotypic and functional diversities the microenvironment, we perform integrative single-cell RNA sequencing analyses on NK from 716 patients with cancer, covering 24 cancer types. We observed heterogeneity cell composition a tumor-type-specific manner. Notably, have identified group of tumor-associated that are enriched tumors, show impaired anti-tumor functions, associated unfavorable prognosis resistance to immunotherapy. Specific myeloid subpopulations, particular LAMP3+ dendritic cells, appear mediate regulation immunity. Our study provides insights into NK-cell-based immunity highlights potential clinical utilities subsets as therapeutic targets.
Language: Английский
Citations
175
Journal of Hematology & Oncology, Journal Year: 2023, Volume and Issue: 16(1)
Published: Aug. 28, 2023
Triple-negative breast cancer (TNBC), a highly aggressive subtype of cancer, negatively expresses estrogen receptor, progesterone and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is main form treatment for patients with TNBC, effectiveness TNBC still limited. The search more effective therapies urgent. Multiple targeted therapeutic strategies have emerged according to specific molecules signaling pathways expressed in TNBC. These include PI3K/AKT/mTOR inhibitors, Notch poly ADP-ribose polymerase antibody-drug conjugates. Moreover, immune checkpoint example, pembrolizumab, atezolizumab, durvalumab, are widely explored clinic. We summarize recent advances therapy immunotherapy aim serving as reference development individualized future.
Language: Английский
Citations
117
Cancers, Journal Year: 2023, Volume and Issue: 15(7), P. 1987 - 1987
Published: March 26, 2023
Breast cancer is the most common in women and leading cause of death. HER2 overexpression found approximately 20% breast cancers associated with a poor prognosis shorter overall survival. Tratuzumab, monoclonal antibody directed against receptor, standard care treatment. However, third patients do not respond to therapy. Given high rate resistance, other HER2-targeted strategies have been developed, including antibodies such as pertuzumab margetuximab, trastuzumab-based drug conjugates trastuzumab-emtansine (T-DM1) trastuzumab-deruxtecan (T-DXd), tyrosine kinase inhibitors like lapatinib tucatinib, among others. Moreover, T-DXd has proven be use HER2-low subtype, which suggests that therapies could successful this recently defined new subclassification. When progress multiple strategies, there are several available; however, treatment options limited, potential combination drugs, immune checkpoint inhibitors, CAR-T cells, CAR-NK, CAR-M, vaccines an interesting appealing field still development. In review, we will discuss highlights pitfalls different combinations overcome metastatic disease resistance
Language: Английский
Citations
82
Smart Medicine, Journal Year: 2024, Volume and Issue: 3(1)
Published: Feb. 1, 2024
Abstract Immune engineering, a burgeoning field within regenerative medicine, involves spectrum of strategies to optimize the intricate interplay between tissue biomaterials and host tissue. These are applied across different types various disease models, which encompasses finely modulating immune response at levels cells factors, aiming mitigate adverse effects like fibrosis persistent inflammation that may arise injury site consequently promote regeneration. With continuous progress in electrospinning technology, immunoregulatory capabilities electrospun fibers have gained substantial attention over years. Electrospun fibers, with their extracellular matrix‐like characteristics, high surface‐area‐to‐volume ratio, reliable pharmaceutical compound capacity, emerged as key players among engineering materials. This review specifically focuses on role fiber‐based emphasizing unique design strategies. Notably, actively engages by responses through four essential strategies: (i) surface modification, (ii) drug loading, (iii) physicochemical parameters, (iv) biological grafting. presents comprehensive overview mechanisms system injured tissues while unveiling adopted orchestrate regulation. Furthermore, explores current developmental trends limitations concerning function drive advancements its full potential.
Language: Английский
Citations
75
Nature Reviews Drug Discovery, Journal Year: 2023, Volume and Issue: 22(12), P. 976 - 995
Published: Oct. 31, 2023
Language: Английский
Citations
60
Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)
Published: Jan. 16, 2024
Abstract As a newly identified checkpoint, T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is highly expressed on CD4 + cells, CD8 natural killer (NK) regulatory cells (Tregs), tumor-infiltrating lymphocytes (TILs). TIGIT has been associated NK exhaustion in vivo individuals various cancers. It not only modulates survival but also mediates exhaustion. the primary ligand of humans, CD155 may be main target for immunotherapy due to its interaction TIGIT. found that anti-programmed death protein 1 (PD-1) treatment response cancer correlated Anti-TIGIT alone combination anti-PD-1 agents have tested immunotherapy. Although two clinical studies advanced lung had positive results, TIGIT-targeted antibody, tiragolumab, recently failed new trials. In this review, we highlight current developments discuss characteristics functions
Language: Английский
Citations
34
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: Feb. 9, 2024
Natural Killer (NK) cells, intrinsic to the innate immune system, are pivotal in combating cancer due their independent cytotoxic capabilities antitumor response. Unlike predominant treatments that target T cell immunity, limited success of immunotherapy emphasizes urgency for innovative approaches, with a spotlight on harnessing potential NK cells. Despite tumors adapting mechanisms evade cell-induced cytotoxicity, there is optimism surrounding Chimeric Antigen Receptor (CAR) This comprehensive review delves into foundational features and recent breakthroughs comprehending dynamics cells within tumor microenvironment. It critically evaluates applications challenges associated emerging CAR-NK therapeutic strategies, positioning them as promising tools evolving landscape precision medicine. As research progresses, unique attributes offer new avenue interventions, paving way more effective precise approach treatment.
Language: Английский
Citations
26
Journal of Molecular Graphics and Modelling, Journal Year: 2024, Volume and Issue: 128, P. 108702 - 108702
Published: Jan. 3, 2024
Language: Английский
Citations
20
Cell Death Discovery, Journal Year: 2024, Volume and Issue: 10(1)
Published: July 10, 2024
Abstract Cancer immunotherapy harnesses the body’s immune system to combat malignancies, building upon an understanding of tumor immunosurveillance and evasion mechanisms. This therapeutic approach reactivates anti-tumor responses can be categorized into active, passive, combined immunization strategies. Active engages recognize attack cells by leveraging host immunity with cytokine supplementation or vaccination. Conversely, passive employs exogenous agents, such as monoclonal antibodies (anti-CTLA4, anti-PD1, anti-PD-L1) adoptive cell transfers (ACT) genetically engineered chimeric antigen receptor (CAR) T NK cells, exert effects. Over past decades, CAR-T therapies have gained significant traction in oncological treatment, offering hope through their targeted approach. However, potential adverse effects associated including release syndrome (CRS), off-tumor toxicity, neurotoxicity, warrant careful consideration. Recently, CAR-NK therapy has emerged a promising alternative landscape immunotherapy, distinguished its innate advantages over modalities. In this review, we will synthesize latest research clinical advancements therapies. We elucidate benefits employing oncology critically examine developmental bottlenecks impeding broader application. Our discussion aims provide comprehensive overview current status future cancer immunotherapy.
Language: Английский
Citations
19